After bonanza market caps and equally steep stock-price fall-offs, Canadian marijuana has a new cash generator: exporting the ...

The incidence of cannabis use disorder associated with schizophrenia almost tripled among Canadian teenagers and adults after ...

Trump says Canada is the problem when it comes to drugs. New data from the Canada Border Services Agency (CBSA) shows this ...

“If cannabis use ‘causes’ schizophrenia, it is absolutely impossible that the rate of schizophrenia would not be going up ...

People who need emergency care or hospitalization for cannabis use disorder are at an elevated risk of premature death within ...

Schizophrenia cases associated with problematic weed use have skyrocketed in the wake of Canada's legalization of marijuana, ...

A new cohort study found that schizophrenia cases related to cannabis use disorder serious enough to warrant a person to seek emergency care increased afte ...

Two new Canadian studies are the largest to date looking at death rates and psychosis associated with cannabis use disorder.

Canopy Growth Q3 sales hit C$74.76 million, surpassing estimates. Medical cannabis revenue rose 16%, while adjusted EBITDA loss improved 61% year-over-year.

Aurora Cannabis (NASDAQ: ACB) surged 45% after reporting record earnings, boosting CGC, TLRY, and CRON stocks.

A new Canadian study shows a tripling of schizophrenia cases linked to cannabis use disorder since the country legalized it.